CMVLF Stock Chart & Stats
$4.40
-$0.25(-16.67%)
At close: 4:00 PM EST
$4.40
-$0.25(-16.67%)
Day’s Range― - ―
52-Week Range$2.60 - $5.04
Previous CloseN/A
Volume1.60K
Average Volume (3M)6.00
Market Cap
$210.09M
Enterprise Value$218.11
Total Cash (Recent Filing)$185.47M
Total Debt (Recent Filing)$82.33M
Price to Earnings (P/E)―
Beta-0.42
Next Earnings
Jul 30, 2026EPS Estimate
-0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.67
Shares Outstanding72,325,455
10 Day Avg. Volume20
30 Day Avg. Volume6
Financial Highlights & Ratios
PEG Ratio-0.10
Price to Book (P/B)6.52
Price to Sales (P/S)6.52
P/FCF Ratio-11.22
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.87
Revenue Forecast (FY)$61.69M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsA TTM gross margin near 79% indicates strong product-level economics tied to proprietary gene‑editing and manufacturing processes. High gross margins create durable capacity to absorb fixed R&D and SG&A, enabling meaningful operating leverage as revenue scales and improving long-term profitability potential.
Revenue Scale ImprovementReported revenue growth metrics and a TTM revenue base (~€68.1M) show improving top‑line scale versus prior troughs. For a clinical‑stage biotech, rising partner/licensing revenues and milestone structures can provide more stable inflows over months, supporting ongoing programs and reducing absolute reliance on one financing event.
Platform & Business ModelCellectis' gene‑editing platform and focus on off‑the‑shelf allogeneic T‑cell therapies represent a structural competitive advantage: scalable manufacturing, broader patient addressability, and multiple partnership/licensing pathways. This platform creates durable optionality across programs and revenue streams.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flow of tens of millions annually signals continued cash consumption to fund R&D and operations. This creates dependency on external financing or partner milestones, shortening runway and constraining strategic choices if capital markets or partner funding become less accessible.
Rising Leverage & Falling EquityHigher leverage combined with a materially reduced equity base weakens balance-sheet flexibility. Elevated debt-to-equity increases financing risk and cost, limits capacity for additional borrowing to fund development, and raises the chance of dilutive or expensive capital raises over the medium term.
Deep Negative ProfitabilityNear‑100% negative net margin and negative EBIT/EBITDA show operating costs far exceed revenues. Without meaningful revenue scale or structural cost reduction, the company lacks operating leverage to reach sustainable profits, increasing reliance on partners and external capital to continue clinical development.
Cellectis SA News
CMVLF FAQ
What was Cellectis SA’s price range in the past 12 months?
Cellectis SA lowest stock price was $2.60 and its highest was $5.04 in the past 12 months.
What is Cellectis SA’s market cap?
Cellectis SA’s market cap is $210.09M.
When is Cellectis SA’s upcoming earnings report date?
Cellectis SA’s upcoming earnings report date is Jul 30, 2026 which is tomorrow.
How were Cellectis SA’s earnings last quarter?
Cellectis SA released its earnings results on May 11, 2026. The company reported -$0.174 earnings per share for the quarter, beating the consensus estimate of -$0.252 by $0.077.
Is Cellectis SA overvalued?
According to Wall Street analysts Cellectis SA’s price is currently Overvalued.
Does Cellectis SA pay dividends?
Cellectis SA does not currently pay dividends.
What is Cellectis SA’s EPS estimate?
Cellectis SA’s EPS estimate is -0.26.
How many shares outstanding does Cellectis SA have?
Cellectis SA has 72,325,455 shares outstanding.
What happened to Cellectis SA’s price movement after its last earnings report?
Cellectis SA reported an EPS of -$0.174 in its last earnings report, beating expectations of -$0.252. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Cellectis SA?
Currently, no hedge funds are holding shares in CMVLF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cellectis SA
Cellectis S.A., a clinical-stage biotechnology company founded in 1999 and headquartered in Paris, France, concentrates on immuno-oncology. The firm engineers therapeutic solutions utilizing gene-edited T-cells, which are modified to display chimeric antigen receptors (CARs) for the specific identification and destruction of cancer cells. Its operations are divided into two principal segments: Therapeutics and Plants. The company's pipeline features several allogeneic CAR T-cell product candidates. These include UCART19, aimed at CD19-expressing hematologic malignancies such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A, developed to treat relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316, targeting renal cell carcinoma; UCART123, for acute myeloid leukemia; and UCART22, addressing B-cell acute lymphoblastic leukemia. Additionally, Cellectis is advancing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. Cellectis has forged significant strategic partnerships and alliances with companies including Allogene Therapeutics, Inc., Les Laboratoires Servier, The University of Texas M.D. Anderson Cancer Center, and Iovance Biotherapeutics. It also maintains a strategic research and development collaboration with Cytovia Therapeutics, Inc.
CMVLF Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in advancing pivotal clinical trials and maintaining a strong financial position, with ongoing collaborations and upcoming strategic events. However, ongoing arbitration and a decrease in cash reserves posed challenges.View all CMVLF earnings summariesTechnical Analysis
Ownership Overview
―
Insiders
―
Mutual Funds
0.02% Other Institutional Investors
99.98% Public Companies and
Individual Investors